This is a promotional meeting organised and funded by Roche Products Ltd.

Prescribing Information:

Tecentriq ®▼ (atezolizumab)

TECENTRIQ, in combination with bevacizumab, paclitaxel and caboplatin, is intended for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, TECENTRIQ, in combination with bevacizumab, paclitaxel and caboplatin, is indicated only after failure of appropriate targeted therapies.

Avastin ® (bevacizumab)

Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. As TECENTRIQ and Avastin are a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.

Job code: M-GB-00001245

This is a promotional meeting organised and funded by Roche Products Ltd.

September 2020

The link you have selected will take you away from this site to one that is not owned or controlled by Roche Products Ltd. Roche Products Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.